LA
CMLFU

Linden Advisors’s CM Life Sciences, Inc. Unit CMLFU Stock Holding History

Linden Advisors’s Portfolio CMLFU Stock Details CMLFU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,100,000
Closed -$22M – 546
2020
Q3 		$22M Buy
+2,100,000
New +$22.1M 0.27% 74

Other funds holding CMLFU

SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BCP
Berylson Capital Partners Boston, Massachusetts $41.2M AUM 0.19% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Linden Advisors's CMLFU Position: Q4 2020 in Review

Linden Advisors sold out of CM Life Sciences, Inc. Unit (CMLFU) in Q4 2020, closing a stake of 2,100,000 shares — an estimated $22M sold.

Linden Advisors first reported a position in CMLFU in Q3 2020 and held it in 1 quarter. The position peaked at $22M in Q3 2020. 42 funds tracked by Wall St. Rank hold CMLFU as of Q4 2020.

  • Linden Advisors reported no remaining CM Life Sciences, Inc. Unit position as of Q4 2020 after selling out during the quarter.
  • Linden Advisors sold 2,100,000 CM Life Sciences, Inc. Unit shares in Q4 2020, an estimated $22M.
  • Linden Advisors first reported a position in CM Life Sciences, Inc. Unit in Q3 2020 and held it in 1 quarter.
  • Linden Advisors's CM Life Sciences, Inc. Unit position peaked at $22M in Q3 2020.
  • 42 funds tracked by Wall St. Rank held CM Life Sciences, Inc. Unit as of Q4 2020.

Based on Linden Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.